Program provides the Only All-in-One Package for Data Collection, Statistical Analysis, Data Visualization, and Publication-Ready Images
CFX Maestro is the only real-time PCR instrument software that integrates statistical analysis, data visualization, and publication-ready graphics production in one platform.
Hercules, CA — June 8, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of CFX Maestro Software for CFX Real-Time Instruments, a complete workflow solution for real-time PCR data collection and analysis. CFX Maestro is the only real-time PCR instrument software that integrates statistical analysis, data visualization, and publication-ready graphics production in one platform. And, like its predecessors, it enables researchers to set up and run qPCR experiments with ease.
“CFX Maestro actually integrates both data collection and later steps like statistical analysis and creating graphs, which makes it really easy to run quickly through your data and do a pre-assessment,” said Leena Kadam, a graduate student in the lab of Sascha Drewlo at Wayne State University.
“Researchers want to focus on results, not process,” said Aaron Burke, Bio-Rad Global Product Manager, Gene Expression Division. “Bio-Rad’s response is to deliver software that makes real-time PCR as painless as possible, from plate setup to data analysis to publication. We’ve also introduced a Mac version of the software, so researchers can analyze their data on a Mac or a PC.”
Unlike other real-time PCR software that requires researchers to export their data into another software package for in-depth analysis, CFX Maestro addresses the needs of researchers during every step of real-time PCR data analysis. The program includes tools to support reference gene selection, efficiency-corrected relative normalization, data visualization (e.g., bar charts, the ability to edit and annotate graphs), statistics (e.g., t-tests and one- and two-way ANOVA), and multiplate analysis.
“CFX Maestro allows us to directly analyze our data and really see if it’s meaningful,” said Sascha Drewlo, PhD, an associate professor in Wayne State’s School of Medicine. “If you have to export data and go back to the office, it is not very handy. So we really rely on software that is easy to use and straightforward."
The intuitiveness of CFX Maestro starts from the beginning with assay design, where researchers can easily set up their plate and run conditions or use a predesigned PrimePCR™ plate and run files that automatically set up plate and run conditions. While other systems may require scientists to set up their plates before performing a run, CFX Maestro permits them to do so before, during, or even after a run, to save time.
For more information on CFX Maestro Software and how it can streamline the way you perform real-time PCR experiments, please visit bio-rad.com/qPCRSoftware.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs over 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan,” “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
For more information contact:
Marie Nguyen
Bio-Rad Laboratories, Inc.
510-741-5312
Marie_Nguyen@bio-rad.com
Ken Li
Chempetitive Group
312-532-4675
kli@chempetitive.com